MedPath

Interleukin-2 Plus Histamine Dihydrochloride in Treating Patients With Acute Myeloid Leukemia

Phase 3
Completed
Conditions
Leukemia
Registration Number
NCT00003991
Lead Sponsor
Maxim Pharmaceuticals
Brief Summary

RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill acute myeloid leukemia cells. Histamine dihydrochloride may prolong remission and reduce the risk of relapse in patients with acute myeloid leukemia in remission.

PURPOSE: Randomized phase III trial to determine the effectiveness of interleukin-2 plus histamine dihydrochloride in treating patients who have acute myeloid leukemia that is in remission following previous therapy.

Detailed Description

OBJECTIVES: I. Compare the efficacy of interleukin-2 plus histamine dihydrochloride (Maxamine) vs no further therapy in prolonging the leukemia free survival in patients with acute myeloid leukemia in first or subsequent complete remission (CR) following consolidation therapy. II. Compare the relapse rate, overall survival, and quality of life in this patient population treated with interleukin-2 plus Maxamine vs no further therapy. III. Compare the remission inversion rate in patients in subsequent CR with this treatment regimen vs no further therapy.

OUTLINE: This is a randomized, open label, parallel, multicenter study. Patients are stratified according to complete remission (first vs subsequent). Patients are randomized to one of two treatment arms. Arm I: Following consolidation chemotherapy or autologous stem cell transplantation, patients receive interleukin-2 subcutaneously followed by histamine dihydrochloride subcutaneously over 5-7 minutes twice daily on days 1-21. Treatment repeats every 6 weeks for 3 courses and then every 9 weeks for 7 courses in the absence of disease relapse or unacceptable toxicity. Arm II: Patients receive no further therapy following consolidation chemotherapy or autologous stem cell transplantation. Quality of life is assessed prior to study, and at visits 6, 7, 10, 11, 16, 17, and 22. Patients are followed for relapse and survival every 3 months for 2.5 years.

PROJECTED ACCRUAL: A total of 360 patients will be accrued for this study.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
360
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (118)

Tampere University Hospital

🇫🇮

Tampere, Finland

Turku University Central Hospital

🇫🇮

Turku, Finland

Tel-Aviv Medical Center-Ichilov Hospital

🇮🇱

Tel-Aviv, Israel

Kaiser Permanente-Southern California Permanente Medical Group

🇺🇸

San Diego, California, United States

Nevada Cancer Center

🇺🇸

Las Vegas, Nevada, United States

Nevada Medical Group-Internal Medicine

🇺🇸

Reno, Nevada, United States

St. Vincent's Hospital

🇦🇺

Sydney, New South Wales, Australia

Emory University Hospital - Atlanta

🇺🇸

Atlanta, Georgia, United States

University of Pennsylvania Cancer Center

🇺🇸

Philadelphia, Pennsylvania, United States

Liverpool Hospital

🇦🇺

Liverpool, New South Wales, Australia

Manchester Royal Infirmary

🇬🇧

Manchester, England, United Kingdom

Royal Perth Hospital

🇦🇺

Perth, Western Australia, Australia

Oncology and Hematology Associates

🇺🇸

Westwood, Kansas, United States

New York Medical College

🇺🇸

Valhalla, New York, United States

Cedars-Sinai Medical Center

🇺🇸

Los Angeles, California, United States

Scripps Clinic

🇺🇸

La Jolla, California, United States

Sidney Kimmel Cancer Center

🇺🇸

San Diego, California, United States

Arizona Cancer Center

🇺🇸

Tucson, Arizona, United States

University of New Mexico Cancer Research & Treatment Center

🇺🇸

Albuquerque, New Mexico, United States

Our Lady of Mercy Medical Center

🇺🇸

Bronx, New York, United States

Newcastle Mater Misericordiae Hospital

🇦🇺

Newcastle, New South Wales, Australia

Peter MacCallum Cancer Institute

🇦🇺

East Melbourne, Victoria, Australia

Maine Center for Cancer Medicine and Blood Disorders

🇺🇸

Scarborough, Maine, United States

Baylor University Medical Center

🇺🇸

Dallas, Texas, United States

Royal North Shore Hospital

🇦🇺

St. Leonards, New South Wales, Australia

West Clinic, P.C.

🇺🇸

Memphis, Tennessee, United States

Wesley Clinic for Hematology/Oncology

🇦🇺

Auchenflower, Queensland, Australia

Kuopio University Hospital

🇫🇮

Kuopio, Finland

CHR de Besancon - Hopital Jean Minjoz

🇫🇷

Besancon, France

Monash Medical Center

🇦🇺

East Bentleigh, Victoria, Australia

London Health Sciences Centre

🇨🇦

London, Ontario, Canada

Klinikum der J.W. Goethe Universitaet

🇩🇪

Frankfurt, Germany

Hopital Edouard Herriot

🇫🇷

Lyon, France

Martin Luther Universitaet

🇩🇪

Halle Saale, Germany

Royal University Hospital

🇨🇦

Saskatoon, Saskatchewan, Canada

Queen Elizabeth II Health Science Center

🇨🇦

Halifax, Nova Scotia, Canada

New York Presbyterian Hospital - Cornell Campus

🇺🇸

New York, New York, United States

Washington University School of Medicine

🇺🇸

Saint Louis, Missouri, United States

Boston Cancer Group

🇺🇸

Memphis, Tennessee, United States

Medizinische Hochschule Hannover

🇩🇪

Hannover, Germany

NSW Breast Cancer Institute

🇦🇺

Westmead, New South Wales, Australia

Centre Hospitalier Universitaire de Quebec, Pavillion de Quebec

🇨🇦

Quebec City, Quebec, Canada

Tallinn Central Hospital

🇪🇪

Tallinn, Estonia

Aalborg Hospital

🇩🇰

Aalborg, Denmark

Odense University Hospital

🇩🇰

Odense, Denmark

Ireland Cancer Center

🇺🇸

Cleveland, Ohio, United States

Western Pennsylvania Hospital

🇺🇸

Pittsburgh, Pennsylvania, United States

Hanson Center for Cancer Research

🇦🇺

Adelaide, South Australia, Australia

Royal Brisbane Hospital

🇦🇺

Brisbane, Queensland, Australia

Princess Alexandra Hospital

🇦🇺

Brisbane, Queensland, Australia

Queen Elizabeth Hospital

🇦🇺

Adelaide, South Australia, Australia

Royal Melbourne Hospital

🇦🇺

Parkville, Victoria, Australia

Seaforth Medical Centre

🇨🇦

Montreal, Quebec, Canada

Hopital Du Sacre-Coeur de Montreal

🇨🇦

Montreal, Quebec, Canada

Vancouver General Hospital

🇨🇦

Vancouver, British Columbia, Canada

Fremantle Hospital

🇦🇺

Fremantle, Australia

Ottawa Regional Cancer Center - General Division

🇨🇦

Ottawa, Ontario, Canada

Lund University Hospital

🇸🇪

Lund, Sweden

Universitats-Krankenhaus Eppendorf

🇩🇪

Hamburg, Germany

Universitaetsklinikum Tuebingen

🇩🇪

Tuebingen, Germany

Medizinische Klinik und Poliklinik

🇩🇪

Heidelberg, Germany

Wellington Hospital

🇳🇿

Wellington, New Zealand

County Hospital (Karnsjukhuset)

🇸🇪

Skovde, Sweden

Helsinki University Central Hospital

🇫🇮

Helsinki, Finland

Rambam Medical Center

🇮🇱

Haifa, Israel

Hadassah University Hospital

🇮🇱

Jerusalem, Israel

Sheba Medical Center

🇮🇱

Ramat Gan, Israel

Kaplan Hospital

🇮🇱

Rehovot, Israel

Hopital Beaujon

🇫🇷

Clichy, France

Huddinge Hospital

🇸🇪

Stockholm, Sweden

County Hospital/Uddevalla

🇸🇪

Uddevalla, Sweden

County Hospital/Vasteras

🇸🇪

Vasteras, Sweden

Staedtische Kliniken Osnabruek

🇩🇪

Osnabruck, Germany

County Hospital/Kalmar

🇸🇪

Kalmar, Sweden

Leeds Teaching Hospital Trust

🇬🇧

Leeds, England, United Kingdom

Universitat Rostock

🇩🇪

Rostock, Germany

Central Hospital

🇸🇪

Karlstad, Sweden

Caritasklinik St. Theresa

🇩🇪

Saarbrucken, Germany

Regional Hospital

🇸🇪

Orebro, Sweden

University Hospital - Uppsala

🇸🇪

Uppsala, Sweden

University of Alabama Comprehensive Cancer Center

🇺🇸

Birmingham, Alabama, United States

Pacific Hematology/Oncology

🇺🇸

San Francisco, California, United States

Henry Ford Hospital

🇺🇸

Detroit, Michigan, United States

University of Oklahoma Health Sciences Center

🇺🇸

Oklahoma City, Oklahoma, United States

Cancer Care Institute of South Texas

🇺🇸

San Antonio, Texas, United States

South Texas Cancer Institute

🇺🇸

San Antonio, Texas, United States

University Hospital of Linkoping

🇸🇪

Linkoping, Sweden

Malmo University Hospital

🇸🇪

Malmo, Sweden

Karolinska Hospital

🇸🇪

Stockholm, Sweden

County Hospital/Sundsvall

🇸🇪

Sundsvall, Sweden

Umea Universitet

🇸🇪

Umea, Sweden

Centre Hospitalier Regional et Universitaire d'Angers

🇫🇷

Angers, France

Bethesda Bone Marrow Stem Cell Transplant Institute

🇺🇸

Boynton Beach, Florida, United States

University of Florida Health Science Center - Jacksonville

🇺🇸

Jacksonville, Florida, United States

Providence Hospital Cancer Center

🇺🇸

Southfield, Michigan, United States

University of Rochester Cancer Center

🇺🇸

Rochester, New York, United States

University of Tartu

🇪🇪

Tartu, Estonia

Hopital Andre Mignot

🇫🇷

Le Chesnay, France

Centre Hospitalier Regional de Lille

🇫🇷

Lille, France

CHR Hotel Dieu

🇫🇷

Nantes, France

Centre Henri Becquerel

🇫🇷

Rouen, France

Zentralklinikum Augsburg

🇩🇪

Augsburg, Germany

Evang. Diakonissenanstalt

🇩🇪

Bremen, Germany

Medizinische Klinik I

🇩🇪

Dresden, Germany

Universitaetsklinikum Charite

🇩🇪

Berlin, Germany

Universitaetsklinik und Strahlenklinik - Essen

🇩🇪

Essen, Germany

Medizinische Poliklinik der Universitat

🇩🇪

Wurzburg, Germany

Rabin Medical Center

🇮🇱

Petach-Tikva, Israel

Klinikum der Universitaet Ulm

🇩🇪

Ulm, Germany

Waikato Hospital

🇳🇿

Hamilton, New Zealand

Canterbury Health Laboratories

🇳🇿

Christchurch, New Zealand

University of Auckland School of Medicine

🇳🇿

Auckland, New Zealand

County Hospital (Malar Hospital)

🇸🇪

Eskilstuna, Sweden

Palmerston North Hospital

🇳🇿

Palmerston North, New Zealand

Sahlgrenska University Hospital

🇸🇪

Gothenburg (Goteborg), Sweden

Birmingham Heartlands and Solihull NHS Trust (Teaching)

🇬🇧

Birmingham, England, United Kingdom

Mater Public Hospital

🇦🇺

South Brisbane, Queensland, Australia

University of Kansas Medical Center

🇺🇸

Kansas City, Kansas, United States

© Copyright 2025. All Rights Reserved by MedPath